Label-retaining liver cancer cells are relatively resistant to sorafenib

Tumor-Initiating Label-Retaining Cancer Cells in Human Gastrointestinal Cancers Undergo Asymmetric Cell Division

(2012) Hong-Wu Xin et al.   STEM CELLS

Activation of Phosphatidylinositol 3-Kinase/Akt Signaling Pathway Mediates Acquired Resistance to Sorafenib in Hepatocellular Carcinoma Cells

(2011) K.-F. Chen et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Isolation of Live Label-Retaining Cells and Cells Undergoing Asymmetric Cell Division via Nonrandom Chromosomal Cosegregation from Human Cancers

(2011) Danielle Hari et al.   STEM CELLS AND DEVELOPMENT

Vorinostat and sorafenib increase ER stress, autophagy and apoptosis via ceramide-dependent CD95 and PERK activation

(2010) Margaret A. Park et al.   CANCER BIOLOGY & THERAPY

Synergistic Activity of Sorafenib and Sulforaphane Abolishes Pancreatic Cancer Stem Cell Characteristics

(2010) Vanessa Rausch et al.   CANCER RESEARCH

Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity

(2010) Amie S. Corbin et al.   JOURNAL OF CLINICAL INVESTIGATION

Stem-cell-like glioma cells are resistant to TRAIL/Apo2L and exhibit down-regulation of caspase-8 by promoter methylation

(2009) David Capper et al.   ACTA NEUROPATHOLOGICA

WNT16B Is a New Marker of Cellular Senescence That Regulates p53 Activity and the Phosphoinositide 3-Kinase/AKT Pathway

(2009) R. Binet et al.   CANCER RESEARCH

Sorafenib

(2009) Gillian M. Keating et al.   DRUGS

Rehabilitation of a Contract Killer: Caspase-3 Directs Stem Cell Differentiation

(2008) Mohammad Abdul-Ghani et al.   Cell Stem Cell

The hepatic stem cell niche: Identification by label-retaining cell assay

(2008) Reiichiro Kuwahara et al.   HEPATOLOGY

Sorafenib in Advanced Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   NEW ENGLAND JOURNAL OF MEDICINE